Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

9.520 -0.160 (-1.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2... 
From Arvinas Inc.
Via GlobeNewswire
Top 3 Health Care Stocks That Are Set To Fly This Month
 
Via Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
These Analysts Revise Their Forecasts On Arvinas After Q4 Results
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Arvinas
 
Via Benzinga
Tuesday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients. 
Via Benzinga
Gapping stocks in Tuesday's session
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Crude Oil Gains 1%; Ciena Earnings Top Views
 
Via Benzinga
Demystifying Arvinas: Insights From 5 Analyst Reviews
 
Via Benzinga
Unveiling 4 Analyst Insights On Arvinas
 
Via Benzinga
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
The companies are looking to use protein degradation to take on some forms of breast cancer. 
Via Investor's Business Daily
Stay updated with the stocks that are on the move in today's pre-market session.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results
 
Via Benzinga
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Snowflake To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Arvinas Inc.
Via GlobeNewswire
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?
U.S. 
Via Benzinga
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
Via The Motley Fool
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Earnings Scheduled For February 11, 2025
 
Via Benzinga
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients
Arvinas and Pfizer share Phase 1b TACTIVE-U trial results showing 62.5% clinical benefit rate and tolerable safety for advanced breast cancer therapy. 
Via Benzinga
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.